- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04800276
Adapted Physical Activity in Patients With Lower Limb Peripheral Arterial Disease (ACTIV'AO)
Adapted Physical Activity in Patients With Lower Limb Peripheral Arterial Disease (ACTIV'AO)
The prevalence of peripheral arterial disease is 12.2% in France. Intermittent claudication is the most common symtom of this disease. During physical exercise, such as walking, blood oxygen (O2) requirements increase. The development of atherosclerosis in the lower limbs, causes narrowing of the arteries and limits the increase in blood flow required for muscular effort. Patients then experience muscle pain, the intensity of which gradually increases until it forces them to stop. After stopping, the pain subsides and disappears in less than 10 minutes.
The location of the pain (calves and/or thighs and/or buttocks) is related to the location of the ischemia (distal in the calf, proximal in the thigh or buttock, or proximo-distal if several locations). This can have different consequences on the biomechanical parameters of walking and muscle activity. To date, the impact of this localization on physical capacity has never been studied.
These limitations are very disabling and impact the quality of life of patients.
In addition, poor lower limb performance is associated with higher mortality. Reducing symptomatology and improving functional abilities is therefore a major issue in patients with peripheral arterial disease. This can be achieved through the practice of an Adapted Physical Activity, an essential recommendation in the care of patients with peripheral arterial disease.
Our main hypothesis is that the physical activity rehabilitation protocol "Activ'AO" will improve the functional capacities of patients with peripheral arterial disease who have followed the program with the localization of ischemia with a greater consideration than in patients in the group following a "standard" APA protocol. Improvements in functional abilities (such as walking) will lead to improvements in quality of life.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Karine MONTACLAIR
- Phone Number: 02 43 43 43 43
- Email: kmontaclair@ch-lemans.fr
Study Locations
-
-
-
Le Mans, France, 72000
- Recruiting
- Centre Hospitalier du Mans
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient with Lower Limb Peripheral Arterial Disease with IPSC < 0.90, arterial stenosis in the lower limbs and intermittent claudication
- No contraindication to physical activity
Exclusion Criteria:
- Severe or unstable cardiopulmonary pathologies, contraindicating exercise training
- Unstable angina or myocardial infarction <3 months
- Severe rheumatological pathology of the lower limbs
- Amputee of a lower or upper limb fitted with a device
- Extensive dermatosis of the lower limbs
- Known NYHA grade III or IV heart failure
- Known severe respiratory pathology
- Parkinson's disease, hemiplegia or paraplegia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: APA with consideration of ischemia localization
|
muscle strengthening targeted on ischemic areas
|
|
EXPERIMENTAL: APA without consideration of ischemia localization
|
global muscle strenghtening
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assess efficacity of Adapted Physical Activity with localization of ischemia on maximum walking distance compared to Adapted Physical activity without localization of ischemia
Time Frame: 12 weeks after inclusion
|
The efficacity of Adapted Physical Activity was assessed by measure of maximum walking distance
|
12 weeks after inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assess efficacity of Adapted Physical Activity with localization of ischemia on walking abilities compared to Adapted Physical activity without localization of ischemia
Time Frame: 12 weeks after inclusion
|
The efficacity of Adapted Physical Activity was assessed by measure of walking speed with actimeter
|
12 weeks after inclusion
|
|
Assess efficacity of Adapted Physical Activity with localization of ischemia on static balance compared to Adapted Physical activity without localization of ischemia
Time Frame: 12 weeks after inclusion
|
The efficacity of Adapted Physical Activity was assessed by measure of balance static with stabilometry Platform.
|
12 weeks after inclusion
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHM-2019/S18/09
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaRecruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
Marissa JarosinskiTerminatedPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
OrbusNeichEucatech AG; Centre Européen de Recherche CardiovasculaireRecruitingPeripheral Arterial Disease | Peripheral Arterial Occlusive DiseaseSpain, Singapore, Belgium, Germany
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Wroclaw Medical UniversityPoznan University of Medical Sciences; Military Institute of Medicine National...RecruitingPeripheral Arterial Disease(PAD)Poland
-
BayerCompleted
-
University of NebraskaRecruitingPeripheral Arterial Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Peripheral Artery Occlusive DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
Clinical Trials on muscle strengthening targeted on ischemic areas
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingAutonomy of Older PeopleFrance
-
National Taiwan University HospitalRecruitingParkinson Disease | Gait Disorders, NeurologicTaiwan